ABAXYS THERAPEUTICS

{
  "events": [
    {
      "kind": "director_renew",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Francisco Javier GARCIA LADONA",
        "address": null,
        "birth_date": null,
        "profession": null,
        "birth_place": null
      },
      "reason": null,
      "subkind": "renewal",
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": "2024-03-27",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de renouveler \u00E0 partir du 27/03/2024 le mandat de Francisco Javier GARCIA LADONA comme administrateur et administrateur d\u00E9l\u00E9gu\u00E9 qui se terminera le 22/03/2030, sous r\u00E9serve de r\u00E9\u00E9lection.",
      "decharge_status": null,
      "mandate_duration": {
        "kind": "until_date",
        "value": "2030-03-22"
      },
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "commissaris_renew",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Guillaume DE VIRON",
        "address": null,
        "birth_date": null,
        "profession": null,
        "birth_place": null
      },
      "reason": null,
      "subkind": "renewal",
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": "2024-03-27",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de renouveler, \u00E0 partir du27/03/2024 le mandat de Guillaume DE VIRON qui se terminera le 22/03/2030, sous r\u00E9serve de r\u00E9\u00E9lection.",
      "decharge_status": null,
      "mandate_duration": {
        "kind": "until_date",
        "value": "2030-03-22"
      },
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    }
  ],
  "notary": {
    "name": null,
    "firm_city": null,
    "firm_name": null,
    "office_city": null,
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": null,
    "filing_date": null,
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decisions": [
    {
      "body": "algemene_vergadering",
      "date": "2020-08-12",
      "unanimous": true
    }
  ],
  "is_correction": false,
  "subject_company": {
    "kbo": "0644.674.965",
    "name_full": "ABAXYS THERAPEUTICS",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": "0460.365.463",
    "org_name": "SRL COMPTA PLAN",
    "person_name": null,
    "org_rep_person_name": "Bruno DEGUELDRE",
    "person_role_at_subject": null
  },
  "co_filed_documents": [],
  "corrected_publication_numac": null
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 274158.72,
      "delta_eur": 120000.0,
      "before_eur": 154158.72,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "org",
          "name": "BBD BioPhenix S.L.U. (BIOBIDE)",
          "share_class": null,
          "liberation_pct": 100.0,
          "contribution_kind": "inschrijvingsrechten_uitgifte",
          "n_shares_subscribed": 1826,
          "contribution_amount_eur": 120000.0
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": null,
        "n_new_shares": 1826,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "inschrijvingsrechten_uitgifte",
      "paid_up_delta_eur": 120000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "capital_increase",
      "after_eur": 324158.72,
      "delta_eur": 50000.0,
      "before_eur": 274158.72,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "Baron Guillaume de VIRON",
          "share_class": null,
          "liberation_pct": 100.0,
          "contribution_kind": "geld",
          "n_shares_subscribed": 318,
          "contribution_amount_eur": 50000.0
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": null,
        "n_new_shares": 318,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "geld",
      "paid_up_delta_eur": 49926.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": 74.0,
      "merger_new_shares_n": 318,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": 824158.72,
      "delta_eur": 500000.0,
      "before_eur": 324158.72,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "org",
          "name": "BBD BioPhenix S.L.U. (BIOBIDE)",
          "share_class": "b\u00E9n\u00E9ficiaires",
          "liberation_pct": null,
          "contribution_kind": "industrie",
          "n_shares_subscribed": 3184,
          "contribution_amount_eur": 500000.0
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": "b\u00E9n\u00E9ficiaires",
        "n_new_shares": 3184,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 157.0
      },
      "decrease_purpose": null,
      "contribution_type": "industrie",
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": "create"
    },
    {
      "kind": "other",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "_demoted_from": "capital_increase",
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "inschrijvingsrechten_uitgifte",
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Nicolas Demolin",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Manage",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2021-11-18",
    "filing_date": "2021-11-16",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "algemene_vergadering",
    "act_date": "2021-10-29",
    "unanimous": true,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": {
    "waived": false,
    "firm_kbo": null,
    "firm_name": "Christophe REMON \u0026 C\u00B0",
    "ibr_number": null,
    "mission_type": "apport_nature",
    "individual_name": "Christophe REMON"
  },
  "subject_company": {
    "kbo": "0644.674.965",
    "name_full": "ABAXYS THERAPEUTICS",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": null,
    "org_name": "Christophe REMON \u0026 C\u00B0",
    "person_name": null,
    "org_rep_person_name": "Christophe REMON",
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "expedition",
    "plan financier",
    "bankattest",
    "verslag bedrijfsrevisor"
  ],
  "shareholders_after": [
    {
      "kbo": null,
      "pct": null,
      "kind": "org",
      "name": "BBD BioPhenix S.L.U. (BIOBIDE)",
      "role": "aandeelhouder",
      "n_shares": 5010,
      "share_class": null
    }
  ],
  "share_classes_after": [
    {
      "n_shares": 24400,
      "class_name": "Gewone Aandelen",
      "capital_share_eur": 324158.72,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 3184,
      "class_name": "Parts b\u00E9n\u00E9ficiaires",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    }
  ]
}